Our Antibacterial Activities

The ongoing Covid-19 pandemic has awakened the world to the critical need for rapid development of vaccines and antiviral treatments against infectious diseases. But there is an even larger threat lurking behind the current outbreak, one that is already killing hundreds of thousands of people around the world and that will complicate the care of many patients across pathologies. It is the hidden threat from antibiotic resistance — bacteria that are not killed by standard antibiotics. Unfortunately, in the pharmaceutical industry as a whole, the pipeline of drugs to manage these deadly infections has nearly run dry.

Debiopharm is at the frontline of this fight with advanced research against multi-drug resistant (MDR) bacteria (e.g. Staphylococcus spp., Acinetobacter). We recognize that the development of novel antibiotic therapies today can help the world be better prepared for resistant bacterial infections of the future. Debiopharm is honored to be working on one of the few new antibiotic classes in development – the Fabl inhibitor class. This family of narrow-spectrum antiobiotics combine very potent activity against specific pathogens while reducing the selective pressure on other bacterial strains and sparing the microbiome.